Sales Support
U.S.:+1-415-871-0703
U.K.:+44-203-289-4040
JAPAN: +81-50-5539-1737
INDIA:+91-848-285-0837
Contact Us
We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
Healthcare and Pharmaceuticals industry

Atypical Antipsychotic Drugs Market 2020 By Manufacturers, Regions, Type, And Application, Forecast To 2026

  • Purchase Options

 

Summary

The global Atypical Antipsychotic Drugs Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2019. 

Overview:

Atypical antipsychotic drugs are used to treat psychosis. These drugs are effective for the treatment of psychosis in a short duration. Aripiprazole, zotepine, paliperidone, asenapine, ziprasidone, quetiapine, sertindole, risperidone, olanzapine, and clozapine are antipsychotic drugs. The global atypical antipsychotic drugs market is divided into six regions, such as North America, South America, Asia Pacific, Europe, Middle East, and Africa.

Drivers:

Increasing prevalence of schizophrenia (a prime cause of psychosis) or increasing prevalence of mental disorders worldwide is expected to propel growth of the global atypical antipsychotic drugs market over the forecast period. Schizophrenia is a chronic and severe mental disorder that affects 20 million people worldwide, according to the World Health Organization. Moreover, individuals with schizophrenia are 2-3 times more likely to die early than the general population. Government initiatives to improve the treatment of people suffering from a mental disorder are also expected to fuel the market growth. Furthermore, an increase in drug abuse is expected to drive the global atypical antipsychotic drugs market growth.

Restraint:

Side effects associated with atypical antipsychotic drugs are expected to impede the global atypical antipsychotic drugs market growth.

Regional Insights:

North America is expected to witness significant growth in the global atypical antipsychotic drugs market due to the increasing prevalence of schizophrenia among the geriatric population and the rising prevalence of psychosis among the youth. According to the Schizophrenia and Related Disorders Alliance of America (SARDAA), around 3.5 million people in the United States are diagnosed with schizophrenia.

Competitive Section:

Key players active in the global atypical antipsychotic drugs market are Qilu Pharmaceutical, Sumitomo Dainippon Pharma, AstraZeneca, Eil Lilly and Company, Sun Pharmaceutical Industries, Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer, Sanis Health, Allergan, Johnson and Johnson, Cardinal Health, and Novartis AG.

In June 2020, Sumitomo Dainippon Pharma launched LATUDA, an atypical antipsychotic agent for schizophrenia and bipolar depression, in Japan.

In November 2017, Otsuka Pharmaceuticals received the U.S. Food and Drug Administration (FDA) approval for Abilify MyCite (antipsychotic drug treatment), which intends to treat Schizophrenia and acute attacks of bipolar disorder.

The Atypical Antipsychotic Drugs Market report highlights product development and growth strategies such as merger and acquisition adopted by market players along with SWOT Analysis, PEST and Porter’s Five Forces analyses of the Atypical Antipsychotic Drugs Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.

The Key Manufacturers covered in this Report:-

  • Novartis AG
  • Cardinal Health
  • Johnson and Johnson
  • Allergan
  • Sanis Health
  • Pfizer
  • GlaxoSmithKline
  • Bristol-Myers Squibb Company
  • Sun Pharmaceutical Industries
  • Eil Lilly and Company
  • AstraZeneca
  • Sumitomo Dainippon Pharma
  • Qilu Pharmaceutical

By the Product Type, the market is primarily segmented into:

  • Risperidone
  • Olanzapine
  • Quetiapine
  • Ziprasidone
  • Others

By Applications, the market is segmented into:

  • Bipolar I Disorder
  • Schizophrenia
  • Schizoaffective Disorder
  • Major Depressive Disorder (MDD)

The Report covers the following Regions:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Philippines
    • Vietnam
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Central & South America
    • Brazil
  • Middle East & Africa
    • Turkey
    • GCC Countries
    • Egypt
    • South Africa

Objective of the Atypical Antipsychotic Drugs Market Report:

  • To assess the size of the market by value and volume
  • Analyze the Atypical Antipsychotic Drugs Market in terms of regions and major countries
  • Highlight recent developments and trends in the market
  • Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
  • Determine share of the Atypical Antipsychotic Drugs Market in terms of various segments such as by product type, application, and end-user
  • Offer accurate projection of the market for the forecast period using state-of –the-art tools and the current primary and secondary research approaches
  • Discuss major factors that impact growth of the Atypical Antipsychotic Drugs Market

The Atypical Antipsychotic Drugs Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Atypical Antipsychotic Drugs Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders:

  • Material suppliers/wholesalers
  • Market Distributors/traders
  • Regulatory bodies
  • Research organizations, and consulting firms
  • Commercial research & developments (R&D)
  • Trade associations and industry bodies
  • Importers and exporters
  • End-use industries

Available Customizations:

Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Table of Contents

1 Study Coverage
1.1 Atypical Antipsychotic Drugs Product Introduction
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Atypical Antipsychotic Drugs Market Size Growth Rate by Type
1.4.2 Risperidone
1.4.3 Olanzapine
1.4.4 Quetiapine
1.4.5 Ziprasidone
1.4.6 Others
1.5 Market by Application
1.5.1 Global Atypical Antipsychotic Drugs Market Size Growth Rate by Application
1.5.2 Bipolar I Disorder
1.5.3 Schizophrenia
1.5.4 Schizoaffective Disorder
1.5.5 Major Depressive Disorder (MDD)
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Atypical Antipsychotic Drugs Market Size
2.1.1 Global Atypical Antipsychotic Drugs Revenue 2014-2025
2.1.2 Global Atypical Antipsychotic Drugs Sales 2014-2025
2.2 Atypical Antipsychotic Drugs Growth Rate by Regions
2.2.1 Global Atypical Antipsychotic Drugs Sales by Regions
2.2.2 Global Atypical Antipsychotic Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Atypical Antipsychotic Drugs Sales by Manufacturers
3.1.1 Atypical Antipsychotic Drugs Sales by Manufacturers
3.1.2 Atypical Antipsychotic Drugs Sales Market Share by Manufacturers
3.2 Atypical Antipsychotic Drugs Revenue by Manufacturers
3.2.1 Atypical Antipsychotic Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Atypical Antipsychotic Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Atypical Antipsychotic Drugs Price by Manufacturers
3.4 Atypical Antipsychotic Drugs Manufacturing Base Distribution, Product Types
3.4.1 Atypical Antipsychotic Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Atypical Antipsychotic Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Atypical Antipsychotic Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type
4.1 Global Atypical Antipsychotic Drugs Sales by Type
4.2 Global Atypical Antipsychotic Drugs Revenue by Type
4.3 Atypical Antipsychotic Drugs Price by Type

5 Breakdown Data by Application
5.1 Overview
5.2 Global Atypical Antipsychotic Drugs Breakdown Data by Application

6 North America
6.1 North America Atypical Antipsychotic Drugs by Country
6.1.1 North America Atypical Antipsychotic Drugs Sales by Country
6.1.2 North America Atypical Antipsychotic Drugs Revenue by Country
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Atypical Antipsychotic Drugs by Type
6.3 North America Atypical Antipsychotic Drugs by Application

7 Europe
7.1 Europe Atypical Antipsychotic Drugs by Country
7.1.1 Europe Atypical Antipsychotic Drugs Sales by Country
7.1.2 Europe Atypical Antipsychotic Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Atypical Antipsychotic Drugs by Type
7.3 Europe Atypical Antipsychotic Drugs by Application

8 Asia Pacific
8.1 Asia Pacific Atypical Antipsychotic Drugs by Region
8.1.1 Asia Pacific Atypical Antipsychotic Drugs Sales by Region
8.1.2 Asia Pacific Atypical Antipsychotic Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Thailand
8.1.10 Malaysia
8.1.11 Philippines
8.1.12 Vietnam
8.2 Asia Pacific Atypical Antipsychotic Drugs by Type
8.3 Asia Pacific Atypical Antipsychotic Drugs by Application

9 Central & South America
9.1 Central & South America Atypical Antipsychotic Drugs by Country
9.1.1 Central & South America Atypical Antipsychotic Drugs Sales by Country
9.1.2 Central & South America Atypical Antipsychotic Drugs Revenue by Country
9.1.3 Brazil
9.2 Central & South America Atypical Antipsychotic Drugs by Type
9.3 Central & South America Atypical Antipsychotic Drugs by Application

10 Middle East and Africa
10.1 Middle East and Africa Atypical Antipsychotic Drugs by Country
10.1.1 Middle East and Africa Atypical Antipsychotic Drugs Sales by Country
10.1.2 Middle East and Africa Atypical Antipsychotic Drugs Revenue by Country
10.1.3 Turkey
10.1.4 GCC Countries
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Atypical Antipsychotic Drugs by Type
10.3 Middle East and Africa Atypical Antipsychotic Drugs by Application

11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Details
11.1.2 Company Business Overview
11.1.3 Novartis AG Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Novartis AG Atypical Antipsychotic Drugs Products Offered
11.1.5 Novartis AG Recent Development
11.2 Cardinal Health
11.2.1 Cardinal Health Company Details
11.2.2 Company Business Overview
11.2.3 Cardinal Health Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Cardinal Health Atypical Antipsychotic Drugs Products Offered
11.2.5 Cardinal Health Recent Development
11.3 Johnson and Johnson
11.3.1 Johnson and Johnson Company Details
11.3.2 Company Business Overview
11.3.3 Johnson and Johnson Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Johnson and Johnson Atypical Antipsychotic Drugs Products Offered
11.3.5 Johnson and Johnson Recent Development
11.4 Allergan
11.4.1 Allergan Company Details
11.4.2 Company Business Overview
11.4.3 Allergan Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Allergan Atypical Antipsychotic Drugs Products Offered
11.4.5 Allergan Recent Development
11.5 Sanis Health
11.5.1 Sanis Health Company Details
11.5.2 Company Business Overview
11.5.3 Sanis Health Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Sanis Health Atypical Antipsychotic Drugs Products Offered
11.5.5 Sanis Health Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Company Business Overview
11.6.3 Pfizer Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Pfizer Atypical Antipsychotic Drugs Products Offered
11.6.5 Pfizer Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Details
11.7.2 Company Business Overview
11.7.3 GlaxoSmithKline Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2014-2019)
11.7.4 GlaxoSmithKline Atypical Antipsychotic Drugs Products Offered
11.7.5 GlaxoSmithKline Recent Development
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Details
11.8.2 Company Business Overview
11.8.3 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Products Offered
11.8.5 Bristol-Myers Squibb Company Recent Development
11.9 Sun Pharmaceutical Industries
11.9.1 Sun Pharmaceutical Industries Company Details
11.9.2 Company Business Overview
11.9.3 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Products Offered
11.9.5 Sun Pharmaceutical Industries Recent Development
11.10 Eil Lilly and Company
11.10.1 Eil Lilly and Company Company Details
11.10.2 Company Business Overview
11.10.3 Eil Lilly and Company Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Eil Lilly and Company Atypical Antipsychotic Drugs Products Offered
11.10.5 Eil Lilly and Company Recent Development
11.11 AstraZeneca
11.12 Sumitomo Dainippon Pharma
11.13 Qilu Pharmaceutical

12 Future Forecast
12.1 Atypical Antipsychotic Drugs Market Forecast by Regions
12.1.1 Global Atypical Antipsychotic Drugs Sales Forecast by Regions 2019-2025
12.1.2 Global Atypical Antipsychotic Drugs Revenue Forecast by Regions 2019-2025
12.2 Atypical Antipsychotic Drugs Market Forecast by Type
12.2.1 Global Atypical Antipsychotic Drugs Sales Forecast by Type 2019-2025
12.2.2 Global Atypical Antipsychotic Drugs Revenue Forecast by Type 2019-2025
12.3 Atypical Antipsychotic Drugs Market Forecast by Application
12.4 North America Atypical Antipsychotic Drugs Forecast
12.5 Europe Atypical Antipsychotic Drugs Forecast
12.6 Asia Pacific Atypical Antipsychotic Drugs Forecast
12.7 Central & South America Atypical Antipsychotic Drugs Forecast
12.8 Middle East and Africa Atypical Antipsychotic Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Atypical Antipsychotic Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Table
List of Tables and Figures

Figure Atypical Antipsychotic Drugs Product Picture
Table Atypical Antipsychotic Drugs Market Segments
Table Key Manufacturers Atypical Antipsychotic Drugs Covered
Table Global Atypical Antipsychotic Drugs Market Size Growth Rate by Type 2019-2025 (K Units) & (Million US$)
Figure Global Atypical Antipsychotic Drugs Sales Market Share by Type in 2018 & 2025
Figure Risperidone Product Picture
Table Major Manufacturers of Risperidone
Figure Olanzapine Product Picture
Table Major Manufacturers of Olanzapine
Figure Quetiapine Product Picture
Table Major Manufacturers of Quetiapine
Figure Ziprasidone Product Picture
Table Major Manufacturers of Ziprasidone
Figure Others Product Picture
Table Major Manufacturers of Others
Table Global Atypical Antipsychotic Drugs Market Size Growth Rate by Application 2019-2025 (K Units)
Figure Global Atypical Antipsychotic Drugs 4900 Sales Market Share by Application in 2018
Figure Bipolar I Disorder
Figure Schizophrenia
Figure Schizoaffective Disorder
Figure Major Depressive Disorder (MDD)
Figure Atypical Antipsychotic Drugs Report Years Considered
Figure Global Atypical Antipsychotic Drugs Market Size 2014-2025 (Million US$)
Figure Global Atypical Antipsychotic Drugs Sales 2014-2025 (K Units)
Table Global Atypical Antipsychotic Drugs Market Size by Regions 2014-2019 (K Units) & (Million US$)
Table Global Atypical Antipsychotic Drugs Sales by Regions 2014-2019 (K Units)
Table Global Atypical Antipsychotic Drugs Sales Market Share by Regions 2014-2019
Figure Global Atypical Antipsychotic Drugs Sales Market Share by Regions 2014-2019
Figure 2018 Global Atypical Antipsychotic Drugs Sales Market Share by Regions
Table Global Atypical Antipsychotic Drugs Revenue by Regions 2014-2019 (Million US$)
Table Global Atypical Antipsychotic Drugs Revenue Market Share by Regions 2014-2019
Figure Global Atypical Antipsychotic Drugs Revenue Market Share by Regions 2014-2019
Figure 2018 Global Atypical Antipsychotic Drugs Revenue Market Share by Regions
Table Global Atypical Antipsychotic Drugs Sales by Manufacturers (2014-2019) (K Units)
Table Global Atypical Antipsychotic Drugs Sales Share by Manufacturers (2014-2019)
Figure Global Atypical Antipsychotic Drugs Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Atypical Antipsychotic Drugs Revenue by Manufacturers (2014-2019) (Million USD)
Table Atypical Antipsychotic Drugs Revenue Share by Manufacturers (2014-2019)
Figure Atypical Antipsychotic Drugs Value Share by Manufacturers in 2018
Table Key Manufacturers Atypical Antipsychotic Drugs Price (2014-2019) (USD/Unit)
Table Atypical Antipsychotic Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Atypical Antipsychotic Drugs Product Type
Table Date of International Manufacturers Enter into Atypical Antipsychotic Drugs Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Atypical Antipsychotic Drugs Sales by Type (2014-2019) (K Units)
Table Global Atypical Antipsychotic Drugs Sales Share by Type (2014-2019)
Figure Global Atypical Antipsychotic Drugs Sales Market Share by Type (2014-2019)
Figure Global Atypical Antipsychotic Drugs Sales Market Share by Type in 2018
Table Global Atypical Antipsychotic Drugs Revenue by Type (2014-2019) (Million US$)
Table Global Atypical Antipsychotic Drugs Revenue Share by Type (2014-2019)
Figure Global Atypical Antipsychotic Drugs Revenue Market Share by Type (2014-2019)
Figure Global Atypical Antipsychotic Drugs Revenue Market Share by Type in 2018
Table Atypical Antipsychotic Drugs Price by Type 2014-2019 (USD/Unit)
Table Global Atypical Antipsychotic Drugs Sales by Application (2014-2019) (K Units)
Table Global Atypical Antipsychotic Drugs Sales Share by Application (2014-2019)
Figure Global Sales Atypical Antipsychotic Drugs Market Share by Application (2014-2019)
Figure Global Sales Atypical Antipsychotic Drugs Market Share by Application in 2018
Figure North America Atypical Antipsychotic Drugs Sales Growth Rate 2014-2019 (K Units)
Figure North America Atypical Antipsychotic Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table North America Atypical Antipsychotic Drugs Sales by Country (2014-2019) (K Units)
Table North America Atypical Antipsychotic Drugs Sales Market Share by Country (2014-2019)
Figure 2018 North America Atypical Antipsychotic Drugs Sales Market Share by Country
Table North America Atypical Antipsychotic Drugs Revenue by Country (2014-2019) (Million US$)
Table North America Atypical Antipsychotic Drugs Revenue Market Share by Country (2014-2019)
Figure 2018 North America Atypical Antipsychotic Drugs Revenue Market Share by Country
Figure United States Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure United States Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Canada Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Canada Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Mexico Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table North America Atypical Antipsychotic Drugs Sales by Type (2014-2019) (K Units)
Table North America Atypical Antipsychotic Drugs Sales Market Share by Type (2014-2019)
Figure 2018 North America Atypical Antipsychotic Drugs Market Share by Type
Table North America Atypical Antipsychotic Drugs Sales by Application (2014-2019) (K Units)
Table North America Atypical Antipsychotic Drugs Sales Market Share by Application (2014-2019)
Figure 2018 North America Atypical Antipsychotic Drugs Market Share by Application
Figure Europe Atypical Antipsychotic Drugs Sales Growth Rate 2014-2019 (K Units)
Figure Europe Atypical Antipsychotic Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Europe Atypical Antipsychotic Drugs Sales by Country (2014-2019) (K Units)
Table Europe Atypical Antipsychotic Drugs Sales Market Share by Country (2014-2019)
Figure 2018 Europe Atypical Antipsychotic Drugs Sales Market Share by Country
Table Europe Atypical Antipsychotic Drugs Revenue by Country (2014-2019) (Million US$)
Table Europe Atypical Antipsychotic Drugs Revenue Market Share by Country (2014-2019)
Figure 2018 Europe Atypical Antipsychotic Drugs Revenue Market Share by Country
Figure Germany Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Germany Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure France Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure France Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure UK Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure UK Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Italy Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Russia Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Europe Atypical Antipsychotic Drugs Sales by Type (2014-2019) (K Units)
Table Europe Atypical Antipsychotic Drugs Sales Market Share by Type (2014-2019)
Figure 2018 Europe Atypical Antipsychotic Drugs Market Share by Type
Table Europe Atypical Antipsychotic Drugs Sales by Application (2014-2019) (K Units)
Table Europe Atypical Antipsychotic Drugs Sales Market Share by Application (2014-2019)
Figure 2018 Europe Atypical Antipsychotic Drugs Market Share by Application
Figure Asia Pacific Atypical Antipsychotic Drugs Sales Growth Rate 2014-2019 (K Units)
Figure Asia Pacific Atypical Antipsychotic Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific Atypical Antipsychotic Drugs Sales by Region (2014-2019) (K Units)
Table Asia Pacific Atypical Antipsychotic Drugs Sales Market Share by Region (2014-2019)
Figure 2018 Asia Pacific Atypical Antipsychotic Drugs Sales Market Share by Region
Table Asia Pacific Atypical Antipsychotic Drugs Revenue by Region (2014-2019) (Million US$)
Table Asia Pacific Atypical Antipsychotic Drugs Revenue Market Share by Region (2014-2019)
Figure 2018 Asia Pacific Atypical Antipsychotic Drugs Revenue Market Share by Country
Figure China Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure China Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Japan Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure South Korea Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure South Korea Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure India Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure India Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Australia Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Indonesia Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Thailand Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Malaysia Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Philippines Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Vietnam Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific Atypical Antipsychotic Drugs Sales by Type (2014-2019) (K Units)
Table Asia Pacific Atypical Antipsychotic Drugs Sales Market Share by Type (2014-2019)
Figure 2018 Asia Pacific Atypical Antipsychotic Drugs Market Share by Type
Table Asia Pacific Atypical Antipsychotic Drugs Sales by Application (2014-2019) (K Units)
Table Asia Pacific Atypical Antipsychotic Drugs Sales Market Share by Application (2014-2019)
Figure 2018 Asia Pacific Atypical Antipsychotic Drugs Market Share by Application
Figure Central & South America Atypical Antipsychotic Drugs Sales Growth Rate 2014-2019 (K Units)
Figure Central & South America Atypical Antipsychotic Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America Atypical Antipsychotic Drugs Sales by Country (2014-2019) (K Units)
Table Central & South America Atypical Antipsychotic Drugs Sales Market Share by Country (2014-2019)
Figure 2018 Central & South America Atypical Antipsychotic Drugs Sales Market Share by Country
Table Central & South America Atypical Antipsychotic Drugs Revenue by Country (2014-2019) (Million US$)
Table Central & South America Atypical Antipsychotic Drugs Revenue Market Share by Country (2014-2019)
Figure 2018 Central & South America Atypical Antipsychotic Drugs Revenue Market Share by Country
Figure Brazil Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Brazil Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America Atypical Antipsychotic Drugs Sales by Type (2014-2019) (K Units)
Table Central & South America Atypical Antipsychotic Drugs Sales Market Share by Type (2014-2019)
Figure 2018 Central & South America Atypical Antipsychotic Drugs Market Share by Type
Table Central & South America Atypical Antipsychotic Drugs Sales by Application (2014-2019) (K Units)
Table Central & South America Atypical Antipsychotic Drugs Sales Market Share by Application (2014-2019)
Figure 2018 Central & South America Atypical Antipsychotic Drugs Market Share by Application
Figure Middle East and Africa Atypical Antipsychotic Drugs Sales Growth Rate 2014-2019 (K Units)
Figure Middle East and Africa Atypical Antipsychotic Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa Atypical Antipsychotic Drugs Sales by Country (2014-2019) (K Units)
Table Middle East and Africa Atypical Antipsychotic Drugs Sales Market Share by Country (2014-2019)
Figure 2018 Middle East and Africa Atypical Antipsychotic Drugs Sales Market Share by Country
Table Middle East and Africa Atypical Antipsychotic Drugs Revenue by Country (2014-2019) (Million US$)
Table Middle East and Africa Atypical Antipsychotic Drugs Revenue Market Share by Country (2014-2019)
Figure 2018 Middle East and Africa Atypical Antipsychotic Drugs Revenue Market Share by Country
Figure Turkey Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Turkey Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure GCC Countries Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure GCC Countries Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure Egypt Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa Atypical Antipsychotic Drugs Sales Growth Rate (2014-2019) (K Units)
Figure South Africa Atypical Antipsychotic Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa Atypical Antipsychotic Drugs Sales by Type (2014-2019) (K Units)
Table Middle East and Africa Atypical Antipsychotic Drugs Sales Market Share by Type (2014-2019)
Figure 2018 Middle East and Africa Atypical Antipsychotic Drugs Market Share by Type
Table Middle East and Africa Atypical Antipsychotic Drugs Sales by Application (2014-2019) (K Units)
Table Middle East and Africa Atypical Antipsychotic Drugs Sales Market Share by Application (2014-2019)
Figure 2018 Middle East and Africa Atypical Antipsychotic Drugs Market Share by Application
Table Novartis AG Company Details
Table Novartis AG Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Novartis AG Recent Development

Table Cardinal Health Company Details
Table Cardinal Health Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Cardinal Health Recent Development

Table Johnson and Johnson Company Details
Table Johnson and Johnson Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Johnson and Johnson Recent Development

Table Allergan Company Details
Table Allergan Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Allergan Recent Development

Table Sanis Health Company Details
Table Sanis Health Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Sanis Health Recent Development

Table Pfizer Company Details
Table Pfizer Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Pfizer Recent Development

Table GlaxoSmithKline Company Details
Table GlaxoSmithKline Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table GlaxoSmithKline Recent Development

Table Bristol-Myers Squibb Company Company Details
Table Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Bristol-Myers Squibb Company Recent Development

Table Sun Pharmaceutical Industries Company Details
Table Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Sun Pharmaceutical Industries Recent Development

Table Eil Lilly and Company Company Details
Table Eil Lilly and Company Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Eil Lilly and Company Recent Development

Table AstraZeneca Company Details
Table Sumitomo Dainippon Pharma Company Details
Table Qilu Pharmaceutical Company Details
Table Global Atypical Antipsychotic Drugs Sales Forecast by Regions 2019-2025 (K Units)
Table Global Atypical Antipsychotic Drugs Sales Market Share Forecast by Regions 2019-2025
Table Global Atypical Antipsychotic Drugs Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global Atypical Antipsychotic Drugs Revenue Market Share Forecast by Regions 2019-2025
Table Global Atypical Antipsychotic Drugs Sales Forecast by Type 2019-2025 (K Units)
Table Global Atypical Antipsychotic Drugs Sales Market Share Forecast by Type 2019-2025
Table Global Atypical Antipsychotic Drugs Revenue Forecast by Type 2019-2025 (Million US$)
Table Global Atypical Antipsychotic Drugs Revenue Market Share Forecast by Type 2019-2025
Table Global Atypical Antipsychotic Drugs Sales Forecast by Application 2019-2025 (K Units)
Table Global Atypical Antipsychotic Drugs Sales Market Share Forecast by Application 2019-2025
Figure North America Atypical Antipsychotic Drugs Sales Growth Rate Forecast (2019-2025) (K Units)
Figure North America Atypical Antipsychotic Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe Atypical Antipsychotic Drugs Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Europe Atypical Antipsychotic Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific Atypical Antipsychotic Drugs Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Asia Pacific Atypical Antipsychotic Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America Atypical Antipsychotic Drugs Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Central & South America Atypical Antipsychotic Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa Atypical Antipsychotic Drugs Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Middle East and Africa Atypical Antipsychotic Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table Key Opportunities and Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Table Market Risks
Figure Porter's Five Forces Analysis
Table Atypical Antipsychotic Drugs Value Chain
Table Atypical Antipsychotic Drugs Customers List
Figure Channels of Distribution
Table Atypical Antipsychotic Drugs Distributors List
Figure Distributors Profiles
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Figure Key Executives Interviewed
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

 

  • Purchase Options

  • Happy To Assist You

Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.

Contact us